阿替利珠单抗联合射频消融术治疗不可切除的肝细胞癌患者临床疗效和安全性研究*

doi:10.3969/j.issn.1672-5069.2025.02.026

摘要/Abstract

摘要： 目的探讨应用阿替利珠单抗联合射频消融术(RFA)治疗不可切除的肝细胞癌(HCC)患者的临床疗效和安全性。方法 2022年3月～2024年4月我院收治的不可切除的HCC患者112例,被随机分为对照组56例,接受RFA治疗,和观察组56例,接受阿替利珠单抗联合RFA治疗。采用ELISA法检测血清干扰素γ(IFN-γ)、转化生长因子β1(TGF-β1)、白介素10(IL-10)和IL-4水平,使用流式细胞术检测外周血淋巴细胞亚群,应用生活质量量表(QLQ-C30)评估生活质量。结果在治疗后,观察组疾病控制率和客观缓解率分别为89.3%和57.1%,均显著高于对照组的64.3%和35.7%(P<0.05);观察组血清IFN-γ、IL-4和IL-10水平分别为(255.3±10.2)ng/mL、(45.3±5.4)μg/mL和(25.5±3.2)μg/mL,均显著高于对照组【分别为(229.9±10.0)ng/mL、(34.6±4.3)μg/mL和(20.2±2.8)μg/mL,P<0.05】,而血清TGF-β1水平为(21.2±3.7)μg/mL,显著低于对照组【(28.2±3.0μg/mL,P<0.05】;观察组外周血CD3⁺和CD4⁺T细胞百分比和CD4⁺/CD8⁺细胞比值分别为(64.1±5.1)%、(33.8±2.8)%和(1.3±0.2),均显著高于对照组【分别为(57.9±5.0)%、(29.0±2.7)%和(1.0±0.2),P<0.05】;观察组QLQ-C30评分显著优于对照组(P<0.05);观察组不良反应发生率为33.9%,显著高于对照组为12.5%(P<0.05)。结论应用阿替利珠单抗联合RFA治疗不可切除的HCC患者具有较好的短期临床疗效,能够提高生活质量,可能与改善了机体免疫功能有关。

关键词: 肝细胞癌, 阿替利珠单抗, 射频消融术, 治疗

Abstract: Objective The aim of this study was to investigate clinical efficacy and safety of radiofrequency ablation (RFA) plus atezolizumab in the treatment of patients with unresectable hepatocellular carcinoma (HCC). Methods A total of 112 patients with unresectable HCC were encountered in our hospital between March 2022 and April 2024, and were randomly assigned to receive RFA in 56 cases, or receive FRA plusatezolizumab combination therapy. Serum interferon-γ, transforming growth factor-β1(TGF-β1), interleukin-10(IL-10)and IL-4 levels were detected by ELISA, peripheral blood lymphocyte subsets were determined by FCA, and quality of life (QOL) was assessed byQLQ-C30 questionaire. Results After treatment, disease control rate and Objective remission rate in the combination group were89.3% and 57.1%, both much higher than 64.3% and 35.7%(P<0.05) in the control; serum IFN-γ,IL-4 and IL-10 levels were(255.3±10.2)ng/mL, (45.3±5.4)μg/mL and (25.5±3.2)μg/mL, all significantly higher than [(229.9±10.0)ng/mL, (34.6±4.3)μg/mL and (20.2±2.8)μg/mL, respectively, P<0.05], while serum TGF-β1 level was (21.2±3.7)μg/mL, significantly lower than [(28.2±3.0μg/mL,P<0.05] in the control group; percentages of peripheralblood CD3⁺ and CD4⁺T cells, and ratio ofCD4⁺/CD8⁺cells were (64.1±5.1)%, (33.8±2.8)% and (1.3±0.2), all significantly higher than[(57.9±5.0)%, (29.0±2.7)% and (1.0±0.2), respectively,P<0.05] in the control; improvement of quality of life in the combination group was much superior to that in the control(P<0.05); incidence of adverse effect in the combination group was 33.9%, much higher than 12.5%(P<0.05) in the control group. Conclusion RFA plus atezolizumab therapy is efficaciousin the treatment of patients with unresectable HCC, with significant improved QOL, which might be related to body immune modulation.

Key words: Hepatoma, Atezolizumab, Radiofrequency ablation, Therapy

严隽瑶, 尹国文, 徐清宇, 尤然, 秦锦霞. 阿替利珠单抗联合射频消融术治疗不可切除的肝细胞癌患者临床疗效和安全性研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 262-265.

Yan Junyao, Yin Guowen, Xu Qingyu, et al. Efficacy and safety of radiofrequency ablation plus atezolizumab in the treatment of patients with unresectable hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2025, 28(2): 262-265.

参考文献

[1] Cheng X, Zhang L, Li J, et al. A multi-criteria decision analysis framework for evaluating first-line therapies for unresectable hepatocellular carcinoma. Cancer Ther Rev, 2022, 49: 34-42.
[2] Li X, Li Q, Zhang J, et al. Efficacy and safety of immune checkpoint inhibitors combined with anti-angiogenesis agents in treating hepatitis B-related unresectable hepatocellular carcinoma. J Clin Oncol, 2022, 40(7): 312-318.
[3] Zhu M, Wang M, Yang Y, et al. Adverse events of atezolizumab in clinical trials: An analysis based on the EudraVigilancedatabase. Cancer Chemother Pharmacol, 2023, 91(3): 563-570.
[4] Liu Z, Zhang J, Yang X, et al. The impact of home-based exercise rehabilitation on the quality of life and adherence in patients with atrial fibrillation after radiofrequency ablation: a longitudinal study. Eur J Cardiovasc Nurs, 2023, 22(5): 397-405.
[5] 陶巧建,仲华根,周绍荣,等. 瑞马唑仑复合小剂量丙泊酚诱导麻醉肝癌切除术患者镇静和认知功能恢复比较研究. 实用肝脏病杂志,2024,27(6):923-926.
[6] 黄英,杨志勇,罗明. 卡瑞利珠单抗联合仑伐替尼治疗晚期原发性肝癌患者疗效和安全性分析. 实用肝脏病杂志,2024,27(4):595-598.
[7] Zhang X, Liu Z, Li H, et al. Efficacy of transcatheter arterial chemoembolization combined with lenvatinib and camrelizumab for advancedhepatocellular carcinoma. J Cancer Res Clin Oncol, 2023, 149(2): 785-795.
[8] 唐小童,于寒冰,郭辉,等. 免疫检查点抑制剂联合抗血管生成治疗在晚期肝癌中的临床观察. 蚌埠医学院学报,2024,49(4):464-468.
[9] Lin L, Zhang Q, Zhang J, et al. Efficacy and safety of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis. Cancer Med, 2022, 11(3): 1243-1253.
[10] 武文华,蔡芝芳,李亚萍,等. 肝动脉化疗栓塞联合射频消融治疗原发性肝癌患者血清炎症因子变化及其对远期生存率的影响. 实用肝脏病杂志,2024,27(6):927-930.
[11] 王震,王硕,张艺琼,等. 大肝癌消融治疗的应用及其进展. 中华肝脏病杂志,2024,32(5):469-473.
[12] Chen J, Wang Z, Zhou Y, et al. Efficacy and safety of FOLFOX-HAIC combined with lenvatinib and immune checkpoint inhibitors in advanced hepatocellular carcinoma with TACE resistance. Cancer Med, 2023, 12(6): 1587-1599.
[13] Zhang J, Liu Y, Wang L, et al. Macrophages regulate immune checkpoint inhibitors efficacy by modulating the PD-L1/STAT3 axis in the tumor microenvironment. Front Immunol, 2022, 13: 814786.
[14] Zhang J, Li Q, Zhang Y, et al. Efficacy and safety of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multicenter real-world study. J Hepatol, 2023, 78(3): 523-530.
[15] Yau T, Kang YK, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a multicenter phase III randomized controlled trial. Lancet Oncol, 2022, 23(5): 720-729.
[16] Wang X, Zhang Z, Wang Y, et al. Adverse effects and hyperprogressive disease in PD-1/PD-L1 inhibitors for cancer treatment: a systematic review. Immunotherapy, 2022, 14(10): 773-788.
[17] Xie Y, Liu T, Yang Z, et al. Evaluation of the efficacy and safety of lenvatinib plus atezolizumab sequential TACE in patients with advanced hepatocellular carcinoma: A phase 2 clinical trial. Cancer Chemother Pharmacol, 2022, 89(3): 413-421.
[18] Zhang J, Yu X, Liang Z, et al. Progress in research on the application of immune checkpoint inhibitors in extensive-stage small cell lung cancer. J Thorac Oncol, 2023, 18(6): 1027-1035.
[19] Xie Z, Wang X, Yang F, et al. The effects of NK cells combined with radiofrequency ablation on liver cancer: T cell subsets and quality oflife. J Cancer Res Ther, 2022, 18(2): 345-352.
[20] He L, Wang Z, Lin J, et al. Comparison of laparoscopic liver resection and radiofrequency ablation on liver function and immune response in patients with primary liver cancer. J Surg Res, 2022, 267: 366-372.

阿替利珠单抗联合射频消融术治疗不可切除的肝细胞癌患者临床疗效和安全性研究^*

Efficacy and safety of radiofrequency ablation plus atezolizumab in the treatment of patients with unresectable hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吕天富, 南琼. 经颈静脉肝内门体分流术治疗肝硬化门静脉高压症患者抗凝治疗研究进展[J]. 实用肝脏病杂志, 2025, 28(2): 165-168.
[2]	李全维, 高明慧, 寇卜心, 柴梦音, 霍云飞, 豆双双, 庞丽君, 石英, 刘晓霓. p65通过调控脂代谢影响HepG2细胞增殖研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 173-177.
[3]	陈婷婷, 丁蓉, 姬文莉, 吴梦秋. 高敏HBV DNA检测技术在低病毒血症慢性乙型肝炎患者抗病毒疗效监测中的应用^*[J]. 实用肝脏病杂志, 2025, 28(2): 178-181.
[4]	钱花, 杨忠祥, 石荔. 核苷(酸)类似物经治的慢性乙型肝炎患者发生低病毒血症影响因素分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 186-189.
[5]	祁婧, 赵小婷, 王婷婷, 高瑞. 接受索磷布韦/达拉他韦治疗的慢性丙型肝炎患者血清NOD样受体热蛋白结构域相关蛋白3水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(2): 194-197.
[6]	钱平安, 姜煜资, 聂红明. 穴位贴敷疗法联合运动处方治疗非酒精性脂肪性肝病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 206-209.
[7]	管海燕, 张慧, 张毅, 王晓兰, 吴婷婷. 肝脂肪变性对泼尼松与硫唑嘌呤联合治疗的自身免疫性肝炎患者治疗应答的影响^*[J]. 实用肝脏病杂志, 2025, 28(2): 214-217.
[8]	孙超, 宋丽萍, 王彬. 异甘草酸镁联合还原型谷胱甘肽治疗化疗药物性肝损伤患者疗效及其血清氧化应激指标的变化研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 222-225.
[9]	何晓非, 陈杰, 赵斌, 陆世峰. 选择性脾胃区减断术与脾切除联合贲门周围血管离断术治疗肝硬化并发门静脉高压症患者疗效对照研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 238-241.
[10]	拾倩, 李莉, 倪昊天. 替诺福韦联合安络化纤丸治疗乙型肝炎肝硬化患者临床疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 242-245.
[11]	程晓洁, 彭星华, 葛海江, 程海超, 张明, 李智峰. 脾栓塞术治疗肝豆状核变性并发中重度脾功能亢进症患者疗效评价^*[J]. 实用肝脏病杂志, 2025, 28(2): 250-253.
[12]	何培, 冯磊, 曹向红, 王佳, 彭传梅, 孔凡斌, 陶春晖, 张振华. RNA m6A甲基化与肝细胞癌的相关性及对肝癌患者预后作用的Meta分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 254-257.
[13]	陈思雨, 庞永平, 宋云鹏, 乔海霞. TACE联合靶向和免疫治疗中晚期肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 258-261.
[14]	周敏, 李涛, 王波玲. 超声造影联合血清PIVKA-Ⅱ水平评估TACE治疗的老年肝细胞癌患者完全缓解价值分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 270-273.
[15]	钟新梅, 闫莉莉, 张冬梅. 细菌性肝脓肿患者临床特征与病原菌分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 286-289.